The HGCSG1901 Study; Multicenter Retrospective Cohort Study Evaluating the Efficacy and Safety of IRIS/Bev in Patients with Metastatic Colorectal Cancer.

The HGCSG1901 Study; Multicenter Retrospective Cohort Study Evaluating the Efficacy and Safety of IRIS/Bev in Patients with Metastatic Colorectal Cancer. - HGCSG1901

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039077

Enrollment

500

Registered

2020-01-08

Start date

2019-12-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who were treated with IRIS / Bev in primary or secondary treatment. 2)Age <=20 years old at the time of diagnosis. 3)patients who have not rejected the participation of this study from the research subjects or their agent(person who is thought to be able to speak for the will and interest of the research subject).

Exclusion criteria

Exclusion criteria: 1)Participation in the clinical trial is determined as unsuitable.

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Overall Survival, Response rate, Disease control rate, Safety, Analysis by UGT1A1 polymorphism, Treatment effect predictor, Examination of prognostic factors	—

Countries

Japan

Contacts

Public ContactKen Ito

Hokkaido University Hospital Cancer Center

kenito0421@med.hokudai.ac.jp011-716-1161

Outcome results